C4 Therapeutics, Inc. (CCCC) NASDAQ
3.07
-0.1(-3.15%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
C4 Therapeutics, Inc.
Address
490 Arsenal Way
Watertown, MA 02472
United States of America (the)
Phone
617 231 0700
Sector
Healthcare
Industry
Biotechnology
Employees
110
First IPO Date
October 02, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Andrew J. Hirsch | Chief Executive Officer, President & Director | 1.38M | 1971 |
| Kenneth C. Anderson | Co-Founder, Independent Director & Member of Scientific Advisory Board | 45,750 | 1951 |
| Paige Mahaney | Chief Scientific Officer | 657,342 | 1970 |
| Kendra Adams | Chief Financial Officer and Head of Corporate Affairs & Treasurer | 869,511 | 1977 |
| Leonard J. Reyno | Chief Medical Officer | 1.03M | 1962 |
| Kelly Schick | Chief People Officer | 0 | 1980 |
| Christopher Nasveschuk | Senior Vice President of Chemistry | 0 | N/A |
| Nathanael S. Gray | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| Mark Mossler | Chief Accounting Officer | 0 | 1974 |
| Courtney Solberg | Senior Manager of Investor Relations | 0 | N/A |
| Isabel Chiu | Senior Vice President of Strategic Alliances & Business Development | 0 | N/A |
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
